Richard Schilsky to Prognosis
This is a "connection" page, showing publications Richard Schilsky has written about Prognosis.
Connection Strength
0.366
-
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583.
Score: 0.101
-
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. J Oncol Pract. 2016 Feb; 12(2):180-1.
Score: 0.077
-
Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010 Jun; 7(6):318-25.
Score: 0.053
-
First-line treatment options for patients with metastatic colorectal cancer. Nat Clin Pract Oncol. 2004 Dec; 1(2):70-1.
Score: 0.036
-
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22; 90(6):1190-7.
Score: 0.035
-
Adjuvant therapy of colon cancer. Semin Oncol. 1995 Dec; 22(6):600-10.
Score: 0.020
-
Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336.
Score: 0.018
-
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200.
Score: 0.009
-
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2584-6.
Score: 0.009
-
Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994 Oct 01; 74(7):1965-73.
Score: 0.005
-
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8.
Score: 0.003